GLP & Metabolic

GLP-SM1

SKU NA-001CAS 910463-68-2MW 4113.6
99.2% HPLCThird-party testedRUO · Research use only

Price range: $45.98 through $93.98

White to off-white solid. CAS 910463-68-2, MW 4113.6. Reconstitute with bacteriostatic water or 0.6% acetic acid. Purity 99.2% by RP-HPLC. Research use only — not for human or veterinary use.

Multi-vial pricing

Currently out of stock

Leave your email and we will notify you when the next lot is available.

HPLC verifiedPurity confirmed per lot
COA includedLot-specific certificate
Cold-chainShipped 2-8°C with packs
Lot traceableDocumented to dispatch
RUOThis product is sold for laboratory research use only. It is not a drug or supplement and is not for human or veterinary consumption, diagnostic or therapeutic use.
Description

GLP-SM1 is a GLP-1 receptor agonist analog supplied by Nano Aminos strictly as a reference material for in-vitro and laboratory research. It is catalogued under CAS 910463-68-2, molecular formula C187H291N45O59, and a molecular weight of 4113.6 g/mol.

Provided as a lyophilized powder (white to off-white solid), GLP-SM1 is part of the Nano Aminos GLP-1 & Metabolic research range and is prepared for research use by reconstitution in bacteriostatic water, 0.6% acetic acid using standard aseptic technique.

Every production lot is characterized by reversed-phase HPLC and mass spectrometry at 99.2% typical HPLC purity and ships with a lot-specific Certificate of Analysis (COA), so identity and purity can be independently confirmed before use. Vials are kept cold and protected from repeated freeze–thaw cycles. GLP-SM1 is available in 5 mg, 10 mg, and 20 mg research sizes.

Related research: browse the full GLP-1 & Metabolic category or compare MOTS-c and 5-Amino-1MQ.

For research use only. Not for human or veterinary use. GLP-SM1 is not a drug, food, or dietary supplement.

Specifications
CompoundGLP-SM1
ClassificationGLP-1 receptor agonist analog
CAS number910463-68-2
Molecular formulaC187H291N45O59
Molecular weight4113.6 g/mol
Purity99.2% by RP-HPLC (area %)
Physical formLyophilized powder
AppearanceWhite to off-white solid
ReconstitutionBacteriostatic water, 0.6% acetic acid
Lab documentation

Each production lot is released against an analytical specification and ships with the corresponding Certificate of Analysis.

Certificate of AnalysisLot 404113699
MethodRP-HPLC / UV 214 nm
Purity (area %)99.2%
IdentityESI-MS confirmed
AppearanceWhite to off-white solid
Storage & handling

Storage. Store lyophilized material at -20°C protected from light and moisture for long-term stability. After reconstitution, keep at 2-8°C and use within the documented in-use window.

Handling. Allow sealed vials to equilibrate to room temperature before opening to limit condensation. Reconstitute with the listed diluent using standard aseptic laboratory technique. Avoid repeated freeze-thaw cycles.

Safety. Handle as a laboratory research chemical. Wear appropriate PPE and follow your institution's chemical-handling and waste-disposal procedures.

Shipping

Dispatch. In-stock orders are processed on business days and shipped with temperature-controlled packaging and gel packs to preserve material integrity in transit.

Tracking. A tracking reference is issued at dispatch. Lab accounts can consolidate shipments and arrange standing orders.

Eligibility. Orders are accepted from researchers, resellers and institutions for laboratory research use only.

Selected research

Literature referencing this compound.

Publications relevant to this molecule, provided for research reference. Inclusion does not imply an approved use or any claim about the products sold here.

Phase 3 RCT
N Engl J Med. 2021;384(11):989–1002
Once-Weekly GLP-SM1 in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al.
Phase 3 RCT
Nat Med. 2022;28:2083–2091
Two-year effects of GLP-SM1 in adults with overweight or obesity (STEP 5)
Garvey WT, Batterham RL, Bhatta M, et al.
Phase 2 RCT
Lancet. 2018;392(10148):637–649
Efficacy and safety of GLP-SM1 vs liraglutide and placebo for weight loss: a phase 2 trial
O'Neil PM, Birkenfeld AL, McGowan B, et al.
Reference

Background reading on peptide chemistry and handling.